Home

Nancy Wysenski

CIK 1294596 · EVP, Chief Commercial Officer · last filed 2026-07-16

Nancy Wysenski is an EVP, Chief Commercial Officer who has filed 85 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing shows the insider was granted $6.2K of CYTK on Jul 16, 2026. Across all open-market trades the lifetime net is −$34.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $20.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$20.22M

Companies

9

Total Filings

85

Lifetime Open-Market Net

-$34.94M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CYTK Director 33,992 $76.76 $2.61M $0 30 2026-07-16
ALKS Director 33,028 $49.17 $1.62M -$1.01M 19 2023-07-10
Provention Bio, Inc. (PRVB) Delisted Director — $24.98 — $0 5 2023-04-27
Dova Pharmaceuticals Inc. (DOVA) Delisted Director 0 — — $0 4 2019-11-12
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Director — — — $0 6 2019-06-11
INO Director 417 $0.67 $279 $0 4 2016-05-16
VRTX EVP, Chief Commercial Officer 32,232 $496.07 $15.99M -$33.93M 11 2012-06-01
ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted Chief Operating Officer 13,054 $0.29 $3.8K $0 3 2009-03-02
NORTH AMERICAN SCIENTIFIC INC (NASI) Delisted Director — — — $0 2 2008-05-01

Recent Filings

85 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-16 CYTK Grant (A) +75 $6.2K EDGAR
2026-05-27 CYTK Grant (A) +2,851 $0 EDGAR
2026-04-15 CYTK Grant (A) +95 $6.2K EDGAR
2026-01-16 CYTK Grant (A) +98 $6.2K EDGAR
2025-10-16 CYTK Grant (A) +99 $6.2K EDGAR
2025-07-16 CYTK Grant (A) +164 $6.2K EDGAR
2025-05-14 CYTK Grant (A) +7,333 $0 EDGAR
2025-04-16 CYTK Grant (A) +162 $6.2K EDGAR
2025-01-06 CYTK Grant (A) +127 $6.2K EDGAR
2024-10-03 CYTK Grant (A) +118 $6.2K EDGAR
Showing 1–10 of 85
Page 1 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.